

# Executive Summary

**CCRM** is a Canadian-led, global public-private partnership that brings together key stakeholders, gap-filling expertise and infrastructure, targeted funding, and a highly trained ecosystem to accelerate the development and commercialization of regenerative medicine-based technologies and cell and gene therapies.

**Unmet Need:** Cell and gene therapies, and regenerative medicine-based products and technologies, have the potential to transform health care, with the promise to treat, manage and perhaps cure some of the most debilitating and costly diseases in the world today. However, many new and potentially life-changing treatments never reach patients because they are not moved from the laboratory to the clinic.

**Opportunity:** Canadian scientific excellence in stem cells, molecules, biomaterials and bioengineering, combined with existing infrastructure, positions CCRM to coordinate product development and company creation and scaling in a capital-efficient manner.

## Business Strategy:

- **Specialized Services:** CCRM provides contract and consulting services to academic researchers, industry and investors, enhancing the capabilities and reputation of the ecosystem.
- **Opportunity Development:** CCRM identifies, supports and de-risks promising new technologies and companies, enhancing deal flow.
- **Strategic Investment:** CCRM invests in opportunities, building sustainability for CCRM and the ecosystem.
- **Biomanufacturing Training:** Through the Canadian Advanced Therapies Training Institute (CATTI), CCRM is growing the industry's manufacturing capabilities by offering training to accelerate the market readiness of the workforce.

## From Concept to Market, our Teams:

- **ATTRACT:** business, regulatory and IP services with commercialization and technology expertise
- **LAUNCH:** technology evaluation and development, supporting company ideation, incubation and launch
- **ADVANCE:** cell reprogramming and engineering, technology translation, product and protocol development
- **BRIDGE:** pre-clinical to commercially-ready cell and gene therapy process optimization and scale-up within the Centre for Advanced Therapeutic Cell Technologies (CATCT)
- **DELIVER:** GMP cell and gene therapy manufacturing within the Centre for Cell and Vector Production (CCVP)
- **SCALE:** market assessments, company diligence, financing, investor engagement and portfolio management through CCRM Enterprises, our investment arm

## Value Proposition:

- Network of business and scientific leaders
- Specialized team and infrastructure to augment academic expertise and facilities
- Industry consortium that reconciles technology push with market pull

## Reasons to Work with CCRM:

- **Industry:** access to state-of-the-art discoveries, facilities and expertise, via CCRM's CDMO subsidiary, OmniaBio Inc.
- **Academics:** business leaders and corporate partners to accelerate commercialization
- **Investors:** risk-mitigated and capital-efficient product development and company launch

## Media Contact:

Stacey Johnson, Vice President, Communications and Marketing  
E: [stacey.johnson@ccrm.ca](mailto:stacey.johnson@ccrm.ca); T: 647-309-1830

June 2024

